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Background
Asthma is a multifaceted disease that presents with a
combination of reversible bronchoconstriction, inflam-
mation, and airway remodeling. Historically, a variety of
in vivo models have been used by preclinical investiga-
tors as surrogates for the disease. However, many of
these models have significant limitations. For example,
rodent models relying solely on TH2 mediated respira-
tory inflammation have inadequate predictability and
clinical translatability because they can only recapitulate
partial aspects of the human disease. In order to align
with human Phase I allergen challenge experiments we
used ascaris sensitive sheep model. This model enables
us to investigate role of different mechanisms on early
and late asthmatics responses.
Methods and materials
After inhaled ascaris antigen challenge, sheep display a
classical airway response featuring an early airway
response (EAR), a late airway response (LAR), and airway
hyperreactivity (AHR), as described by Abraham et al.
(1983) [1]. Compound can be administered either topically
(via inhalation) or systemically prior to the inhaled chal-
lenge. A range of compounds and mechanisms have been
investigated in this model.
Results
Standard of care anti-inflammatory compounds such as
corticosteroids and leukotriene inhibitors show little
inhibition of the EAR at low doses but completely inhi-
bit the LAR and AHR. Novel anti-inflammatory targets
such as Chemoattractant receptor-homologous molecule
expressed on T-helper type 2 cells (CRTH2) inhibitor, MK-
7246, also show little inhibition of the EAR at low doses
and blocked the LAR and AHR. Broncho-constrictors like
the Β2-adenergic antagonist, fomoterol, greatly inhibit the
EAR (~85%) but have less of an effect on the LAR (~60%).
Conclusion
Cumulative data from this model has shown to be a good
predictor for Phase 1 allergen challenge trial. Standard of
care compounds and novel mechanisms used perform
similarly in human trials as they did in ascaris sensitive
sheep model. This model offers some key element of air-
ways reactivity function similar to human asthma.
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